Doing less on purpose: fixed-duration regimens tested against treatment until progression, risk-adapted observation, and the evidence needed before an established therapy can safely be shortened or withheld.
Long-term follow-up (median exceeding 10 years) of NRG Oncology RTOG 0539 validates a risk-adapted meningioma strategy: observation after gross total or subtotal resection for low-risk (WHO grade 1) disease, and radiotherapy for intermediate- and high-risk disease.
Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.
Phase 3 randomized trial of 909 patients with previously untreated CLL across 174 sites in 13 countries